文献速递胸部肿瘤

ALINA试验:阿来替尼辅助治疗切除后ALK阳性NSCLC的生活质量与安全性

Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2026-01-01

ALINA是一项全球3期开放标签随机试验,比较阿来替尼与铂类化疗辅助治疗切除后ALK阳性NSCLC。安全性方面阿来替尼3-4级不良事件以肌酸磷酸激酶升高为主,因不良事件停药更少;生活质量和身体功能在治疗12周即出现临床意义改善并维持2年。

要点

  • 阿来替尼组3-4级不良事件以肌酸磷酸激酶升高(6%)最常见,化疗组以中性粒细胞减少(10%)最常见。
  • 阿来替尼因不良事件停药率5%,低于化疗的13%。
  • 阿来替尼治疗12周时身体疼痛、角色生理、心理健康、社会功能及活力领域较基线有临床意义改善,并维持2年。

核心结论

  • 对于切除后ALK阳性NSCLC,阿来替尼辅助治疗安全性可控,生活质量改善并在2年治疗期间维持。

研究设计与样本

  • 全球3期开放标签随机ALINA试验,257例切除后ALK阳性IB(≥4 cm)-IIIA期NSCLC患者按1:1随机分配。
  • 阿来替尼组130例接受口服600 mg每日两次共24个月,化疗组127例接受静脉铂类化疗4个3周周期。
  • 安全性在安全性可评估人群中分析(阿来替尼128例,化疗120例),生活质量在意向治疗人群中分析。

主要发现

  • 阿来替尼组最常见3-4级不良事件为血肌酸磷酸激酶升高(8/128,6%)、丙氨酸氨基转移酶升高(2/128,2%)和血胆红素升高(2/128,2%)。
  • 化疗组最常见3-4级不良事件为中性粒细胞计数下降(12/120,10%)、中性粒细胞减少(10/120,8%)和恶心(5/120,4%)。
  • 治疗相关严重不良事件阿来替尼组2/128(2%),化疗组8/120(7%);两组均无不良事件相关死亡。
  • 因不良事件停药阿来替尼组7/128(5%),化疗组15/120(13%)。

临床怎么用

  • 对于切除后ALK阳性NSCLC,阿来替尼辅助治疗安全性可控且可维持生活质量,支持其作为新的标准治疗选择。

局限性

  • 生活质量为探索性终点,非主要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with resected, ALK-positive non-small-cell lung cancer (NSCLC), adjuvant alectinib significantly improved disease-free survival versus platinum-based chemotherapy in the global, phase 3, open-label, randomised ALINA trial. We report safety and health-related quality-of-life (HRQoL) outcomes from the ALINA trial. METHODS: Eligible patients aged 18 years or older with resected, ALK-positive, stage IB (≥4 cm)-IIIA NSCLC (per the American Joint Committee on Cancer and the Union for International Cancer Control Cancer Staging Manual 7th edition) and an Eastern Cooperative Oncology Group performance status of 0-1 were randomly assigned (1:1) via a block-stratified randomisation method to receive oral alectinib (600 mg twice daily) for 24 months or intravenous platinum-based chemotherapy for four 3-week cycles. Randomisation was stratified according to disease stage and race. The primary endpoint, previously reported, was disease-free survival. Safety was a secondary endpoint and HRQoL was an exploratory endpoint. Safety was assessed by the investigator as per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5·0 until 28 days after the last alectinib dose or chemotherapy cycle. HRQoL was assessed via the Short-Form 36-item health survey version 2 (SF-36v2) questionnaire at baseline, every 3 weeks to week 12, then every 12 weeks until disease recurrence, consent withdrawal, death, or week 96. Norm-based scoring was applied; clinically meaningful changes were defined using the SF-36v2 manual. Safety was assessed in the safety-evaluable population and HRQoL in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT03456076) and is ongoing. FINDINGS: Between Aug 16, 2018, and Dec 8, 2021, 257 patients were assigned to receive alectinib (n=130) or chemotherapy (n=127). 123 (48%) patients were male and 134 (52%) were female; 143 (56%) were Asian. The safety-evaluable population comprised 128 patients who received alectinib and 120 patients who received chemotherapy; median duration of safety follow-up was 24·8 months (IQR 22·0-24·9) in the alectinib group and 3·7 months (IQR 3·7-3·8) in the chemotherapy group. The safety of adjuvant alectinib was generally consistent with its known profile. The most common grade 3-4 adverse events were blood creatine phosphokinase increased (eight [6%] of 128), alanine aminotransferase increased (two [2%] of 128), and blood bilirubin increased (two [2%] of 128) in the alectinib group, and neutrophil count decreased (12 [10%] of 120), neutropenia (ten [8%] of 120), and nausea (five [4%] of 120) in the chemotherapy group. Serious treatment-related adverse events occurred in two (2%; one each with appendicitis and pneumonitis) of 128 patients in the alectinib group and eight (7%) of 120 patients in the chemotherapy group ( most common were gastrointestinal disorders in three [3%] patients). No deaths due to adverse events were reported in either group. There were fewer discontinuations due to adverse events with alectinib (seven [5%]) versus chemotherapy (15 [13%]). A clinically meaningful difference in improvement from baseline was seen at week 12 for bodily pain, role physical, mental health, social functioning, and vitality SF-36v2 domains with alectinib; improvements in physical and mental HRQoL were maintained over 2 years of active treatment (at week 96, mean Mental Component Summary score: 49·9 [SD 10·4]; mean Physical Component Summary score: 48·8 [SD 7·2]) and reached levels similar to the general population (population norm: 50). INTERPRETATION: For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment. Together with the disease-free survival benefit seen in ALINA, these data support adjuvant alectinib as an important new standard-of-care for patients with resected ALK-positive NSCLC. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Dziadziuszko R, Ahn JS, Barlesi F, et al. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2026. PMID: 42636834. doi:10.1016/S1470-2045(26)00283-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。